Form 4: Director Natalie Holles Receives LeonaBio Stock Options

Director Natalie C. Holles was granted 56,000 stock options in LeonaBio, Inc. as part of the company's 2026 Equity Incentive Plan.

Summary

• Director Natalie C. Holles received a grant of 56,000 stock options on May 5, 2026.
• The options have an exercise price of $9.63 per share.
• The options are scheduled to vest monthly over a 36-month period.
• The expiration date for these options is May 4, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Issuance of new options results in potential future dilution for existing shareholders.

Risks

• Vesting is contingent upon the director remaining a Service Provider to the issuer.

Future Outlook

The options vest monthly over 36 months, indicating a long-term retention strategy for the director.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practice in the biotechnology sector to ensure leadership alignment with company performance milestones.

Comparison to Industry Standards

• The 36-month vesting schedule is consistent with standard industry practices for director equity compensation.
• The use of an Equity Incentive Plan is a common mechanism for biotech firms to attract and retain board talent.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.

Next Steps

• Vesting of options to commence monthly starting one month after the grant date.

Key Dates

Keywords

LeonaBio, LONA, Form 4, Insider Trading, Stock Options, Director Compensation